The therapy being developed utilizes Altea Therapeutics’ PassPort transdermal technology to deliver an active pharmaceutical ingredient to the patient.
Under the terms of the agreement, Teikoku Seiyaku will pay Altea Therapeutics a signing fee, additional payments upon completion of certain development milestones, and undisclosed royalties on net sales.
Teikoku Seiyaku has an option to negotiate terms for exclusive Japanese market rights for certain additional products based on the PassPort system.
“This is a first in what is expected to be a number of collaborations based on our proprietary PassPort system technology that enables painless, efficient transdermal delivery of sustained therapeutic levels of proteins and water-soluble molecules from a skin patch”, stated Eric Tomlinson, president and CEO of Altea Therapeutics.